A PHASE I/II TRIAL TO ASSESS THE SAFETY AND TOLERANCE OF ESCALATING DOSES OF A HUMAN ANTI-CYTOMEGALOVIRUS MONOCLONAL ANTIBODY (SDZ MSL-109) IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND CMV RETINITIS: